Anrotinib, or Anrotinib Hydrochloride Capsules, fatigue is its common adverse reaction, it is recommended to rest, appropriate strengthening exercise, if necessary, stop or change the drug. This drug is a multi-targeted receptor tyrosine kinase inhibitor, which can inhibit the proliferation of a variety of tumor cell lines, and is suitable for the treatment of non-small cell lung cancer patients. Common adverse reactions include hypertension, malaise, hand and foot skin reactions, abnormal liver function, and abnormal thyroid function. When fatigue occurs, patients are advised to take bed rest, strengthen nutrition and exercise appropriately in order to improve immunity and enhance physical fitness. If the patient’s fatigue is serious, consult the doctor in time to stop or change the drug. The use of the drug should be carried out in accordance with the doctor’s instructions. It is forbidden for those who are allergic to the drug, forbidden for patients with central type squamous lung cancer or with the risk of hemoptysis, forbidden for those with severe hepatic and renal insufficiency, and forbidden for pregnant and lactating women.